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Abstract 
By definition, probiotics are to provide health benefits, and are expected not to cause any adverse 
effects in the general population. Recently, it has been suggested that probiotics, and in particular 
lactobacilli are contributing to human obesity. Here, we critically review the data available on this 
topic. The main misconception in this hypothesis is that growth in livestock and children equals 
with obesity in adults. The former two are expected to grow and probiotics may, by reducing 
disease risk, contribute to an improved growth. It is not correct to extrapolate this growth (of all 
tissues) to body weight gain (growth of adipose tissue) in adults. Furthermore, when looking at 
animal models of obesity, it even appears the lactobacilli may potentially contribute to a reduction 
in body weight. Epidemiological studies lend strength to this. We therefore conclude that there is no 
evidence that consumption of lactobacilli or probiotics in general would contribute to obesity in 
humans. 
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 Introduction 
Probiotics are, by definition, considered to provide a health benefit to the consumer 
[WHO/FAO2002]. Being components of functional foods and dietary supplements, probiotics are 
expected not to have any side effects upon consumption by members of the general population. A 
few recent publications have suggested that consumption of probiotics (Raoult, 2009) and in 
particular certain Lactobacillus species (Million et al., 2012) is associated with human obesity also 
reduced faecal levels of Bifidobacterium animalis and Methanobrevibacter smithii have been 
suggested to be associated with obesity (Million et al., 2011). A food manufacturer’sprime concern 
is safety of the products it is producing; this is no different for probiotic products. As obesity is 
a serious health concern and thereby a food safety issue, the hypothesis that certain species of 
Lactobacillus would be contributing to obesity deserves to be investigated. Concerns on this 
hypothesis have earlier been published [Delzenne and Reid, 2009]. However, we feel that the latest 
publication (Million et al., 2012) in support for the hypothesis has a serious number of weaknesses 
that we feel need to be addressed. 
 
Weight gain; livestock vs. human adults 
In the report by Million and co-workers (2012) a meta-analysis is presented to determine if 
consumption of different Lactobacillus containing probiotics is associated with a species specific 
effect on body weight. Due to the limited availability of human data (3 studies included), the data 
was combined with observations from a larger number (30) of animal studies; predominantly farm 
animals.
By combining data from livestock and from infants to explain weight gain and obesity in fully-
grown adult humans, Million and co-workers assume that growth at young age and obesity in 
adulthood are synonymous. However, while both involve body weight gain, the former is desirable 
and normal while the latter is undesirable. Probiotics are used in livestock to optimize the genetic 
potential for growth in young animals. The observed weight gain is a positive response to improved 
gut and immune health and less disease challenge and is typically manifested as lean muscle gain, 
not adipose tissue (Callaway and Ricke, 2012). Body composition of gained weight in livestock 
(lean vs. fat mass) is not considered in this meta-analysis, only the number on the scale. Equating 
muscle growth in young livestock and infants with obesity in humans is therefore incorrect. For 
similar reasons, have antibiotics been used in livestock as growth promoters; they counteract 
negative environmental challenges such as infections and allow the animal to grow closer to it’s 
genetic maximum (Gustafson and Bowen, 1997). Although both antibiotics and probiotics are 
effective in promoting growth in young livestock by improving health and reducing the risk of 
diseases, the modes of action are different. Probiotics are used to enhance the healthy microbial 
homeostasis in the gut and the intestinal mucosa and have direct effects on host functions such as 
the immune system – thereby improving the host defenses against pathogens. Antibiotics, on the 
other hand, are active against a broad range of microbes and suppress both the pathogenic microbes 
as well as the healthy gut microbiota. 
 
Weight gain; children vs. adults 
The presumed Lactobacillus-caused obesity hypothesis, also equates growth in infants, which 
follows a similar pattern as growth in young production animals, with body weight gain and obesity 
in adulthood. In the case of L. acidophilus, the majority of the human data included in the meta-
analysis (Million et al., 2012) comes from a single large infant study from the 1950’s, which 
represent over 800 cases out of the 879 human subjects included in the analysis (Robinson and 
Thompson, 1952). In infants, good growth is desired (this would have been especially true for those 
post-WWII infants included in the study) and a reduced body weight would have been an 
undesirable outcome. Body weight gain in infants is not to be considered as “obesity”, as it relates 
to the normal growth of all the tissues in the body and normal increase in height. Probiotic-mediated 
improved growth in the post-WWII infants can easily be explained by reduced incidence of disease. 
Especially in children, probiotics seem to be able to reduce the risk for or duration of various 
diseases e.g. respiratory tract infections (Hao et al., 2011) and diarrhea (Salari et al., 2012). As with 
young production animals, it is very likely that reduced incidence and/or duration of disease is 
associated with improved growth; but not obesity. The authors of the meta-analysis themselves have 
given the L. acidophilus infant study the lowest quality score and estimated it to have high risk of 
bias. Despite this, the study has been included as a cornerstone in the analysis as it contributes 90% 
of the human data and a quarter of all of the included cases; the remaining three quarters are 
livestock. 
 
Lactobacilli and body weight 
In the case of the L. acidophilus review, of the included studies, only one study is potentially 
relevant to human adults, although the link with obesity is still missing; this is the study by de Roos 
and co-workers (1999) in healthy, non-obese adults. The authors of this study concluded that the 
differences in the weight gain in the probiotic group and placebo group were negligible; differences 
in means were 40g and 210g at two different time points. The direction of the differences was not 
disclosed as the weight changes between the groups were virtually equal and non-significant. A 
more relevant human study in overweight adults was performed by Andreasen and co-workers 
(2010); this study was not included in the review. In this study, no changes in weight were reported, 
but the consumption of L. acidophilus NCFM resulted in improved insulin sensitivity (which is 
often impaired in obesity). 
The weight difference contributed to L. acidophilus is suggested by Million and co-workers (2012) 
to be 1½ kg for a 70 kg human. It is not clear whether this is weight gain per consumption of L. 
acidophilus or for the duration of the study; which in the case of production animals means a life 
time. Extrapolating the latter to humans (which is not appropriate) would mean a 1½ kg increase 
over your adult life. One can dispute the clinical relevance of that, particularly since the data 
presented by Million and co-workers (2012) suggest that the weight gain is related to growth at 
infancy and young age (nearly all data comes from young livestock or human infants). 
It has been also suggested that lactobacilli probiotics may have a weight-reducing effect (Kootte et 
al., 2012). The data supporting the anti-obesity effect mainly comes from studies utilizing 
experimental animal models of obesity and diabetes. Unlike young livestock, these animal models 
are relevant for the study of obesity. The animals studied are adults, and their weight gain is 
obesity-related and often linked to the consumption of high-energy diets. In their meta-analysis, 
Million and co-workers (2012) also observed a weight reducing effect for, in particular 
Lactobacillus gasseri. The weight reduction quoted for L. gasseri is 6 kg for a 70 kg human; 
however, again it is unclear if this is per consumption or for life time consumption. Intriguingly, all 
included results contributing to the anti-obesity result of L. gasseri come from studies assessing 
probiotic effects in adult animal models and from a study with obese human adults. As with other 
lactobacilli, consideration of livestock data would change the conclusions. For example, a study by 
Baker et al.  (2010) demonstrated that the presence of L. gasseri in the intestinal tract, contrary to 
the conclusions by Million et al. (2012), was associated with improved growth in weaning piglets. 
General conclusion from the data presented by Million and co-workers is that irrespective of the 
Lactobacillus species, the studies assessing the effect of lactobacilli in adult humans (overweight or 
obese) or in animal models of obesity suggest that probiotics either have no effect on weight or they 
reduce the weight and obesity. At the same time, studies in young livestock suggest a growth-
promoting effect for probiotics. These conclusions are perfectly in alignment with each other, since 
growth in young livestock has nothing to do with obesity in humans, as discussed above.   
In terms of timing, contrary to what has been suggested by Million et al., the increased prevalence 
of probiotics in food does not correlate with the increased prevalence of obesity. Obesity has been 
rising sharply from the 1970’s, but the inclusion of probiotics in foods has really started to rise 
sharply in the 2000’s – some 30 years after the beginning of the obesity phenomenon (Jankovic et 
al., 2010). Furthermore, probiotics have historically been included in foods first in Japan, followed 
by Europe and only recently in the US. Yet the rise in obesity has followed the opposite sequence, 
starting in the US, followed by Europe and only to a limited extent in Japan. 
 
Lactobacilli in daily nutrition 
From historical and evolutionary stand-point, the consumption of gram-positive bacteria 
(predominantly lactobacilli) in the human diet has reduced greatly with industrialization and 
modernization of the food processing and storage. In the pre-industrial age, the use of fermented 
foods – rich in lactobacilli- was much more prevalent than it is today. The bacterial load of food in 
the pre-industrial age has been estimated to be over 1000 times higher than they are today 
(Bengmark, 1998). Moreover, the during most part of human evolution, drying or burying food in 
caves and holes was the only method for preserving food, and these methods lead to natural 
fermentation of food – predominantly by lactobacilli. Probiotics offer a safe means for restoring the 
historically and evolutionary important balance between lactobacilli-containing diet and human 
health. 
Epidemiological studies link consumption of lactobacilli with lower incidence of metabolic 
disorders including obesity. Consumption of yoghurt, high in lactobacilli, has been reported to be 
inversely associated with metabolic disorders (Beydoun et al., 2008) and with waist circumference, 
hypertension and metabolic syndrome (Azadbakht et al., 2005), and weight loss (Mozaffarian et al., 
2012). While another study did not report significant correlations between yoghurt consumption and 
reduced body weight, it did detect beneficial effects on blood pressure (Snijder et al., 2007). 
 
Conclusions 
In all, we feel that there is no evidence that probiotics or lactobacilli are associated with human 
obesity. If anything, the data from the studies with obese humans or with experimental animal 
models of obesity suggest that certain Lactobacillus probiotics may actually be effective in reducing 
obesity. Intervention trials in adults would be welcome to test the effects of lactobacilli on human 
obesity. In fact, it is likely that several of the probiotic studies that have been performed in the past 
have registered body weight at the beginning and the end of the intervention. This data, that may 
not have been published as it was not considered relevant, should be revisited and may already in 
the short term provide an answer to the postulated obesity risk posed by consumption of certain 
Lactobacillus species. A recent epidemiological study published in the New England Journal of 
Medicine already gives a glimpse of the effects of lactobacilli on body weight management on a 
population level. Combining three U.S. cohorts (together 120 877 humans!) Mozaffarian et al. 
(2012) observed that daily consumption of yogurt was associated with a weight loss of 0.37 kg over 
a period of 4 years. This weight reducing effect was stronger than for any other food type, including 
fruits, vegetables, whole grain products and nuts. In this study, different types of yoghurt were not 
distinguished and the data includes the consumption of plain yoghurt as well as probiotic (including 
L. acidophilus) fortified yoghurt. Intriguingly, other dairy products did not have similar effect as 
yoghurt, giving a strong hint that the efficacy of the yoghurt in reducing weight loss is not due to 
the dairy matrix but due to the lactic acid bacteria fermentation.  
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